Singapore markets closed
Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,022.21 -29.20 (-0.58%) Dow
37,753.31 -45.66 (-0.12%) Nasdaq
15,683.37 -181.88 (-1.15%) Bitcoin USD
62,162.06 -260.77 (-0.42%) CMC Crypto 200
885.54 0.00 (0.00%)
Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 67.31 |
| Open | 67.35 |
| Bid | 66.92 x 400 |
| Ask | 66.96 x 400 |
| Day's range | 66.89 - 67.54 |
| 52-week range | 66.89 - 87.87 |
| Volume | |
| Avg. volume | 7,420,538 |
| Market cap | 83.46B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 14.87 |
| EPS (TTM) | 4.50 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 3.08 (4.60%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 79.65 |
PR NewswireGILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA
Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV). An official announcement was made at a Gilead-hosted symposium titled "Partnering for Global Health Equity: Case Studies from Around the World," held during the World Hepatitis Summit ("Summit") in Lisbon.
ZacksXilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.
ZacksGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
© 2024 Yahoo. All rights reserved.